From the Guidelines
MenQuadfi is associated with mild side effects, including fever, headache, injection site erythema, and dizziness, which are generally short-lived and resolve within a few days 1. The most frequently reported adverse events after MenQuadfi vaccination are:
- Fever, affecting 16.8% of recipients
- Headache, affecting 16.0% of recipients
- Injection site erythema, affecting 14.6% of recipients
- Dizziness, affecting 13.4% of recipients These side effects are consistent with the immune system's response to the vaccine and are typically mild and self-limiting. Serious adverse events, such as Guillain-Barré Syndrome (GBS), are rare, with 86 reported cases out of 8,592 reports, although the diagnosis has not been validated by medical records for all reports 1. Additionally, 24 deaths were reported, with 11 attributed to meningococcal infection, and the remaining 13 due to various other causes, including cardiac, neurologic, and infectious causes, with no identifiable pattern 1. It is essential to note that the benefits of MenQuadfi vaccination in preventing potentially life-threatening meningococcal disease outweigh the risks of temporary side effects. If severe or persistent side effects occur, especially signs of an allergic reaction, such as difficulty breathing, hives, or swelling of the face and throat, immediate medical attention should be sought.
From the Research
Side Effects of MenQuadfi
- The side effects of MenQuadfi, a quadrivalent meningococcal conjugate vaccine, have been studied in several clinical trials 2, 3.
- According to these studies, MenQuadfi has been found to have a similar safety profile to other meningococcal conjugate vaccines, with most side effects being mild and temporary 2, 3.
- Common side effects of MenQuadfi include pain, redness, and swelling at the injection site, as well as fatigue, headache, and muscle pain 3.
- Serious adverse events have been rare in clinical trials of MenQuadfi, and the vaccine has been found to be well-tolerated in individuals of all ages, from 2 years to 97 years old 2, 3.
- The immunogenicity and safety of MenQuadfi have been compared to those of other meningococcal conjugate vaccines, and it has been found to be noninferior in terms of immunogenicity and similar in terms of safety 3.
Comparison to Other Meningococcal Vaccines
- MenQuadfi has been compared to other meningococcal conjugate vaccines, such as MenACWY-D, in terms of immunogenicity and safety 4, 3.
- These studies have found that MenQuadfi has a similar immunogenicity profile to other meningococcal conjugate vaccines, with high seroresponse rates for all four serogroups (A, C, W, and Y) 4, 3.
- The safety profile of MenQuadfi has also been found to be similar to that of other meningococcal conjugate vaccines, with most side effects being mild and temporary 4, 3.
Clinical Trials and Studies
- Several clinical trials and studies have been conducted to evaluate the safety and immunogenicity of MenQuadfi 2, 4, 3.
- These studies have included individuals of all ages, from 2 years to 97 years old, and have found MenQuadfi to be well-tolerated and immunogenic in all age groups 2, 4, 3.
- The results of these studies have supported the approval of MenQuadfi for use in individuals 2 years of age and older 2, 3.